Skip to main
IVVD
IVVD logo

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd Inc has successfully closed a $57.5 million public offering, which significantly bolsters its financial resources to support ongoing antibody development programs. The company’s focus on innovative antibody solutions for viral diseases, particularly its candidates ADG20 and VYD222, positions it to excel in addressing pandemic threats, thereby enhancing its growth potential in a rapidly evolving market. Furthermore, the shift in valuation metrics forward from year-end 2025 to year-end 2026 reflects a positive trend, contributing to an optimistic long-term financial outlook for Invivyd.

Bears say

Invivyd Inc. has experienced a downward revision in expectations concerning its market share for PEMGARDA among immunocompromised patients, indicating a potential challenge in achieving projected revenue targets in this segment. Additionally, a significant dilution from a capital raise has prompted a reduction in the price target from $3.00 to $1.00, reflecting concerns over investor value and future earnings potential. These factors contribute to a negative outlook for the company's stock, as they suggest weakening market dynamics and potential financial instability.

Invivyd Inc (IVVD) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.